(Q47236623)

12 January 2018

meta-analysis

0 references

title

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis (English)

1 reference

12 January 2018

main subject

acute coronary syndrome

1 reference

1 reference

1 reference

1

J W Eikelboom

1 reference

12 January 2018

S S Anand

2

1 reference

12 January 2018

K Malmberg

3

1 reference

12 January 2018

J I Weitz

4

1 reference

12 January 2018

J S Ginsberg

5

1 reference

12 January 2018

S Yusuf

6

1 reference

12 January 2018

language of work or name

English

0 references

publication date

1 June 2000

1 reference

12 January 2018

published in

The Lancet

1 reference

12 January 2018

volume

355

1 reference

12 January 2018

issue

9219

1 reference

12 January 2018

page(s)

1936-1942

1 reference

12 January 2018

Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Inv

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Are we mortgaging the medical profession?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Molecular and cellular biology of blood coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

New antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Low-molecular-weight heparins: pharmacologic profile and product differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Aspirin, heparin, or both to treat acute unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Aspirin versus heparin in the acute phase of unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Reactivation of unstable angina after the discontinuation of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902324-2

7 January 2021

10.1016/S0140-6736(00)02324-2

Identifiers

DOI

1 reference

12 January 2018

PubMed ID

10859038

1 reference

12 January 2018